Partner and manager of a real estate and development company specializing in multi-family housing across the United States.

Director, Commercial Strategy & Planning, JAPAC Region, 2012 - 2014Oversaw all aspects of commercial diligence and planning for Amgen’s expansion to Asia. Led cross-functional team to develop recommendations including entry timing, product portfolio strategy and supporting financials. • Delivered recommendation on Amgen’s Asia Entry Strategy leading to corporate endorsement and resourcing.• Drove commercial diligence for strategic partnering in China. Joint venture agreement signed with Betta Pharma (China).• Led distribution diligence and negotiations across 10 markets in Asia.• Negotiated first commercialization agreement and developed launch strategy with partner in Thailand, for G-CSF franchise.

Vice President, Kirin-Amgen, Inc., 2006-2014 • Alliance lead of Amgen’s 30 year joint venture with Kyowa Hakko Kirin, with 2014 royalties of $400M (Sales of >$10B).• Negotiated over 30 new agreements impacting R&D, operations, finance and marketing• Was awarded Amgen’s 'Commercial Impact Award' for securing clinical development funding• Managed all aspects of governance meetings including clinical, commercial, shareholders' and board of director's meetings

Global Marketing Lead (GML) across 3 programs including in-line and late-stage assets. Co-lead and managed concurrently, each cross-functional product strategy team. • AMG145 (P2) - Led process to identify device optimization partner for Amgen’s PCSK9 program.• GML AMG423 (P2). Worked closely with Cytokinetics to optimize commercial rationale for on-going partnering on this cardiac myosin activator for heart failure.• GML for Aranesp Oncology (Marketed). Managed global commercial planning including life-cycle investment and on-going commercial resourcing.• GML for Aranesp Heart Failure (P3). Delivered “standing start launch playbook” to minimize commercial resourcing.

Deal team lead for commercial organization responsible for global licensing and acquisitions diligence. Worked directly with Global Marketing VP to develop governance structure on worldwide new market expansion activity. • Global commercial lead for business development opportunities across bone, cardiovascular, inflammation, neurology, oncology and “out of strategy” opportunities.• Led commercial assessment resulting in two new licensing deals and acquisition of Abgenix.• Co-lead of market expansion governance structure.

US launch lead for Aranesp (erythropoietin stimulating agent) in peri-surgical setting.• Led commercial launch planning for Aranesp’s peri-surgery indication• Delivered cross-functional commercial strategy assessments for Aranesp across six markets, including HCV, HIV, and critical care medicine.

• Led commercial planning for calcimimetics - Amgen’s first small molecule program for primary and secondary hyperparathyroidism: - Developed initial launch and life-cycle plans earning corporate sponsorship • Completed marketing research on cinacalcet to drive packaging, tableting and brand name development work that led to current presentations and trade names.• Supported business development across nephrology and neurology.